iShares MSCI Argentina & Global Exposure ETF AGT 深 滬
已收盤 08-22 16:00:00 美东时间
26.38
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 26.38
- 總市值 527.60万
- 52周最高 31.2413
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 19.95
- 委 比 0.00%
- 總股本 20.00万
- 歷史最高 31.4788
- 量 比 0
- 振 幅 0.00%
- 歷史最低 11.4114
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多加速出海！一大建材龙头豪掷过亿美元欲收购南美建材零售商 | 盘后公告精选
一大建材龙头拟斥资1.23亿美元全资收购南美建材零售商；某上市公司研发的非洲猪瘟疫苗获批进入临床试验；一锂矿公司旗下子公司被责令立即停止锂资源开采……
07-17 21:06
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the di...
07-09 20:30
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Apogee Therapeutics will announce Phase 2 APEX Part A 16-week data for APG777 on July 7, 2025, followed by a webcast at 8:00 a.m. ET. The webcast will discuss results related to the treatment of inflammatory and immunology conditions like atopic dermatitis, asthma, and COPD. The live event can be accessed via the provided links, with a replay available afterward.
07-06 22:00
CRISPR Therapeutics Reports Progress on Gene-Based Treatments for Cardiovascular Diseases with New Data on CTX310 and CTX320
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs.
06-26 19:13
